You have 9 free searches left this month | for more free features.

ER-positive, PR-positive, HER2-negative

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Alkaline Glucosodiene Molecules
  • (no location specified)
Jul 14, 2023

HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)

Active, not recruiting
  • HER2-positive Breast Cancer
  • TQB2440 injection + Trastuzumab + Docetaxel
  • Perjeta + Trastuzumab + Docetaxel
  • Chongqing, Chongqing, China
  • +5 more
Aug 3, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Boston (NERATINIB,

Not yet recruiting
  • Stage IV (Metastatic) Breast Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 25, 2021

After Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
  • TN ER-/PR-/HER2- Breast Cancer
  • +3 more
  • Standard Trimodality Breast Imaging
  • Minneapolis, Minnesota
    University of Minnesota Masonic Cancer Center
Aug 13, 2021

Metastatic Breast Cancer Trial in Athens

Recruiting
  • Metastatic Breast Cancer
    • Athens, Greece
      Hellenic Society of Medical Oncology
    Feb 9, 2021

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

    Not yet recruiting
    • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    • (no location specified)
    Sep 26, 2023

    Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

    Not yet recruiting
    • Breast Cancer
    • Cancer of the Breast
    • VENTANA MIB-1 Ki67 assay
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Apr 18, 2023

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Triple Negative Breast Cancer, HER2-negative Breast Cancer Trial in Tampa (HER2 - primed Dendritic cells, HER3 - primed

    Recruiting
    • Triple Negative Breast Cancer
    • HER2-negative Breast Cancer
    • HER2 - primed Dendritic cells
    • HER3 - primed Dendritic cells
    • Tampa, Florida
      Moffitt Cancer Center
    Jan 10, 2023

    HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer Trial in Belgium, France (Pertuzumab and

    Recruiting
    • HER2-positive Breast Cancer
    • +3 more
    • Pertuzumab and tratuzumab fixed dose combination
    • Trastuzumab emtansine
    • Auchenflower, Australia
    • +84 more
    Jan 16, 2023

    ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

    Recruiting
    • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
    • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    • Montpellier, France
    • +1 more
    Nov 16, 2022

    Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

    Not yet recruiting
    • Estrogen-receptor-positive Breast Cancer
    • +3 more
    • elacestrant, palbociclib, abemaciclib, ribociclib
    • Chicago, Illinois
      Northwestern University
    Sep 25, 2023

    Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

    Completed
    • Breast Neoplasms
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Oct 26, 2022

    ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

    Active, not recruiting
    • ER+ HER2- Advanced Breast Cancer
    • Chuo-ku, Japan
    • +2 more
    Jan 24, 2023

    Breast Cancer Trial (Giredestrant, Giredestrant plus triptorelin, Anastrozole plus triptorelin)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jun 13, 2023

    Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

    Active, not recruiting
    • Breast Neoplasms
    • Chuo Ku, Japan
    • +1 more
    Dec 19, 2022

    Older Women With ER Positive, HER2 Negative Early Breast Cancer

    Enrolling by invitation
    • Breast Cancer Female
    • Translational study
    • Sutton, United Kingdom
      The Royal Marsden NHS Foundation Trust
    Feb 8, 2023

    Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

    Not yet recruiting
    • Breast Cancer
    • Ovarian Function Suppression + Aromatase Inhibitor
    • Adjuvant Chemotherapy + Ovarian Function Suppression
    • (no location specified)
    May 19, 2023

    ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)

    Recruiting
    • ER+, HER2- Advanced Breast Cancer
    • Metastatic Breast Cancer
    • TFX06 tablet
    • Luoyang, Henan, China
    • +1 more
    Jun 25, 2023

    Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

    Suspended
    • Anatomic Stage I Breast Cancer AJCC v8
    • +23 more
    • Short-Term Fasting
    • Chemotherapy
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 23, 2023

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    Breast Cancer Trial in Sarasota, Nashville (AC699)

    Recruiting
    • Breast Cancer
    • Sarasota, Florida
    • +1 more
    Jan 3, 2023

    Breast Cancer, Brain Metastases Trial in Guangzhou (Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant)

    Recruiting
    • Breast Cancer
    • Brain Metastases
    • Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
    • Guangzhou, Guangdong, China
    • +1 more
    Apr 24, 2022